Lila, Alexander M. http://orcid.org/0000-0002-6068-3080
Mazurov, Vadim I. http://orcid.org/0000-0002-0797-2051
Denisov, Lev N. http://orcid.org/0000-0002-2102-8374
Nesmeyanova, Olga B. http://orcid.org/0000-0002-5599-8248
Ilivanova, Elena P. http://orcid.org/0000-0002-9312-3768
Eremeeva, Anna V. http://orcid.org/0000-0002-1267-0074
Usacheva, Julia Valentinovna http://orcid.org/0000-0002-3377-7700
Dokukina, Ekaterina A. http://orcid.org/0000-0002-6759-673X
Chernyaeva, Ekaterina V. http://orcid.org/0000-0002-7589-8033
Ivanov, Roman A. http://orcid.org/0000-0002-9573-4183
Clinical trials referenced in this document:
Documents that mention this clinical trial
A phase III study of BCD-055 compared with innovator infliximab in patients with active rheumatoid arthritis: 54-week results from the LIRA study
https://doi.org/10.1007/s00296-019-04359-9
Article History
Received: 28 March 2019
Accepted: 28 June 2019
First Online: 10 July 2019
Compliance with ethical standards
:
: Alexander M. Lila, Vadim I. Mazurov, Lev N. Denisov, Olga B. Nesmeyanova, Elena P. Ilivanova declare that they have no conflict of interest. Anna V. Eremeeva, Julia V. Usacheva, Ekaterina V. Chernyaeva, Ekaterina A. Dokukina and Roman A. Ivanov Employees of JCS BIOCAD.
: All patients were informed, and their informed consents were obtained prior to the study. The information on all Ethics Committees and approval dates is presented in Supplementary Material B.